 | | Vol. 12.06 – 19 February, 2021 |
| |
|
|
| The authors describe an androgen-dependent prostate cancer patient-derived xenograft model from treatment-naïve, soft tissue metastasis.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists demonstrated that MAPK4 activated androgen receptor (AR) by enhancing GATA2 transcriptional expression and stabilizing GATA2 protein through repression of GATA2 ubiquitination/degradation. MAPK4 expression correlated with AR activation in human castration-resistant prostate cancer.
[Journal of Clinical Investigation] |
|
|
|
| Prostate cancer cells harboring an mRNA decapping 3 (EDC3) serine 161A mutation showed markedly decreased growth, migration, and invasion in tissue culture and in xenograft models.
[EMBO Reports] |
|
|
|
| An in vitro study with the castration resistant prostate cancer cell exhibited a significant photothermal therapeutic effect as well as enhanced thermodynamic therapy via generating free radicals.
[Nanoscale] |
|
|
|
| The authors found that EWI-2 localized on both the cell membrane and exosomes regulated the distribution of miR-3934-5p between cells and exosomes.
[Molecular Oncology] |
|
|
|
| Scientists investigated the mechanism of SChLAP1 (second chromosome locus associated with prostate-1) on microRNA expression in prostate cancer.
[Cell Death & Disease] |
|
|
|
| Investigators probed the functions of BRG1 on a background of prostate cancer to investigate how BRG1 controls gene expression programs and cancer cell behavior.
[Clinical Epigenetics] |
|
|
|
| Scientists combined single cell Raman spectroscopy with group and basis restricted non-negative matrix factorization to identify individual biochemical changes associated with radiation exposure in three human cancer cell lines.
[Scientific Reports] |
|
|
|
| Researchers enhanced the acute activation of the unfolded protein response (UPR) using radiation and ONC201, a UPR activator. Treating prostate cancer cells with ONC201 quickly increased the expression of all the key regulators of the UPR and reduced oxidative phosphorylation, with cell death.
[Scientific Reports] |
|
|
|
| The authors in vitro analyzed the combinatory effects of calcitriol and transforming growth factors beta (TGF-β) on cell growth and apoptosis using PC-3 and DU145 human prostate cancer cell lines.
[Journal of Steroid Biochemistry and Molecular Biology] |
|
|
|
|
| Scientists provide an overview of the potential response prediction biomarkers and synergistic combinations studied in the preclinical and clinical stages, which may expand the population of patients with prostate cancer who may benefit from PARP inhibitors.
[Acta Pharmacologica Sinica] |
|
|
|
| Investigators summarize the multiple factors that may contribute to the therapeutic burden of patients with castration-resistant prostate cancer, including the interplay between age, comorbidities, concomitant medications, the use of androgen receptor inhibitors, and financial distress.
[Prostate Cancer and Prostatic Diseases] |
|
|
|
|
| Telix Pharmaceuticals Limited announced that the Ministry of Health of the Czech Republic is the first European health authority to grant a national authorization allowing the use of TLX591-CDx, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.
[Telix Pharmaceuticals Limited (Globe Newswire, Inc.)] |
|
|
|
| Ultimovacs ASA announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the company’s Tetanus-Epitope Targeting (TET)-platform.
[Ultimovacs ASA] |
|
|
|
|
| September 5 – 8, 2021
Exeter, England, United Kingdom |
|
|
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | The Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Oslo University Hospital – Oslo, Norway |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
